e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

9.490 +0.080 (+0.85%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗

November 14, 2025

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Via Stocktwits

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗

November 13, 2025

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.

Via Benzinga

Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗

November 13, 2025

Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it.

Via Investor's Business Daily

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗

November 13, 2025

The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.

Via Stocktwits

Keep an eye on the top gainers and losers in Wednesday's session. ↗

November 05, 2025

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 06, 2025

Via Benzinga

Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗

August 06, 2025

Via Benzinga

Analyst Ratings for Day One Biopharmaceutical ↗

November 07, 2023

Via Benzinga

The Latest Analyst Ratings for Day One Biopharmaceutical ↗

September 12, 2023

Via Benzinga

Where Day One Biopharmaceutical Stands With Analysts ↗

August 08, 2023

Via Benzinga

Day One (DAWN) Q2 Revenue Jumps 313% ↗

August 05, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 05, 2025

Via Benzinga

Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss ↗

August 05, 2025

Day One Biopharmaceuticals reports Q2 2025 earnings with revenue growth but wider-than-expected loss, causing an 11.8% stock drop. OJEMDA sales rise 10% QoQ, while pipeline advances.

Via Chartmill

Biotech Investing: How PRVs Can Unlock Major Opportunities

February 05, 2025

Biotech Investing: How PRVs Can Unlock Major Opportunities

Via News Direct

Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2024

Via Benzinga

Bank of America Says Buy These 3 Stocks for a Double-Digit Rally ↗

August 14, 2024

Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%.

Via InvestorPlace

Topics Economy

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 01, 2024

Via Benzinga

DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗

July 30, 2024

DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

July 25, 2024

Via Benzinga

Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal ↗

June 22, 2024

FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting...

Via Talk Markets

DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 ↗

May 06, 2024

DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Dow Up Over 340 Points As Stocks Snap Back ↗

October 30, 2023

The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well.

Via Talk Markets

Topics Stocks

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 26, 2023

Via Benzinga

$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying ↗

October 23, 2023

Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy